Primary Tumor Site Affects Survival in Patients with Gastroenteropancreatic and Neuroendocrine Liver Metastases

Table 2

Factors associated with prolonged survival among patients with neuroendocrine liver metastases on univariate analysis.

Variable		Median survival (months)	95% CI	value
Hospital type				<0.001
Community Cancer Program	163	48.5	37.4 – NR
Comprehensive Community Cancer Program	720	57.8	48.8 – 66.9
Academic/Research Program	986	NR	60.4 – NR
Integrated Network Cancer Program	212	48.6	40.3 – 54.7
Age				<0.001
(61 years)	1157	NR	65.1 – NR
(61 years)	1031	44.4	38.6 – 52.0
Gender				0.99
Female	1034	62.6	54.8 – NR
Male	1154	60.4	54.9 – NR
Race				0.23
Asian or Pacific Islander	34	NR	NR – NR
Black	313	65.1	62.6 – NR
Other or unknown	48	NR	35.6 – NR
White	1793	60.2	54.9 – NR
Hispanic				0.99
Hispanic	88	NR	52.1 – NR
Non-Spanish; non-Hispanic	2013	60.4	56.0 – NR
Unknown	87	NR	38.2 – NR
Charlson comorbidity index				<0.001
Charlson 0 or none	1666	60.4	56.7 – NR
Charlson 1	388	NR	44.1 – NR
Charlson 2 or more	134	41.9	24.4 – NR
Radiation therapy				0.36
No radiation therapy	2016	62.6	56.7 – NR
Radiation therapy	142	49.8	37.1 – NR
Chemotherapy				<0.001
Chemotherapy	543	46.5	35.8 – 54.9
No chemotherapy	1525	66.9	60.2 – NR
Extrahepatic metastatic sites				<0.001
No extrahepatic metastatic sites	2026	65.1	60.4 – NR
Extrahepatic metastatic sites	162	22.4	17.0 – 29.8
Surgery				<0.001
No surgery	878	33.0	29.1 – 37.4
Distant site surgery only	41	33.2	21.9 – 66.9
Primary site surgery only	625	NR	60.4 – NR
Primary and distant site surgery	644	NR	65.1 – NR